Juniper Biomedical Secures Seed Funding to Accelerate Growth and Innovation in Pelvic Health Disorders.
The company's first application will offer long-term, precision therapy for patients with mixed urinary incontinence (MUI), which affects nearly 1 in 3 women.
- The company's first application will offer long-term, precision therapy for patients with mixed urinary incontinence (MUI), which affects nearly 1 in 3 women.
- "We believe that Juniper Biomedical has tremendous potential for growth and disruption in pelvic health in the historically underserved patient populations," said Larry Derose, founder of Auroral Holdings.
- Juniper Biomedical is developing dramatically better therapies for the millions of women and men who suffer in silence from pelvic health conditions like urinary incontinence, bowel incontinence, pelvic pain, sexual dysfunction, and pelvic floor disorders.
- Our solutions leverage a highly precise, low-power neuromodulation micro-implant that delivers a unique type of therapy to pelvic nerves.